Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NASDAQ: NTRB, NTRBW) is a developer of prescription transdermal pharmaceutical products, with a primary focus on its AVERSA abuse-deterrent transdermal technology and its lead product candidate, an abuse-deterrent fentanyl patch. The Nutriband news stream highlights how the company is advancing this technology platform, interacting with regulators, and managing its corporate structure to support product development.
Readers of the Nutriband news page can follow regulatory and clinical development updates, including the company’s reported meetings with the U.S. Food and Drug Administration on the Chemistry, Manufacturing, and Controls plans and the 505(b)(2) NDA pathway for AVERSA Fentanyl. News items also cover Nutriband’s summaries of FDA feedback on in vitro studies to characterize abuse-deterrent properties and its intention to move toward an IND filing in support of a Human Abuse Potential clinical study.
The company’s releases also describe intellectual property developments, such as a provisional patent application to enhance AVERSA technology and U.S. patent actions related to abuse and misuse deterrent transdermal systems, alongside references to a broad patent portfolio covering AVERSA in multiple countries. Corporate and capital markets news includes announcements of a preferred stock dividend tied to future FDA approval of AVERSA Fentanyl, the sale of a majority stake in subsidiary Pocono Pharmaceutical to EarthVision Bio, and Nutriband’s inclusion in Russell indexes.
Additional coverage includes partnership and collaboration news, such as agreements with Kindeva Drug Delivery for product development, Brand Institute for commercial brand name creation, and a non-binding Letter of Intent with the Qvanta Group to explore advanced technology support for abuse-deterrent pharmaceutical innovation. Investors and observers can use this page to review how Nutriband presents its progress on AVERSA Fentanyl, its stance on issues like illicit versus prescription fentanyl, and its participation in investor conferences and public communications.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) is showcasing its innovations at the 2023 Transdermal and Microneedle Conference in London on January 23-24, 2023. CEO Gareth Sheridan will present on January 24 at 11:00 a.m. GMT, focusing on enhancing transdermal technologies to minimize liability regarding abusable medications. COO Dr. Alan Smith will join a panel discussion at 11:40 a.m. GMT about microneedle applications in drug delivery. The conference will also feature industry leaders including Merck and GSK. Nutriband's AVERSA technology aims to prevent drug abuse, emphasizing safety in chronic pain treatments.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has dual-listed on Upstream, a platform for digital securities and NFTs, enhancing its accessibility to global investors. The listing became effective on January 5, 2023, allowing trades in real-time through Upstream's transparent order book. A commemorative NFT for this listing is also available. CEO Gareth Sheridan emphasized the listing's value for shareholders and the company’s mission to reach a modern investor base. However, U.S. investors are only allowed to liquidate existing holdings on Upstream.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced its dual listing on Upstream, commencing January 5, 2023. This move positions Nutriband as the first company to utilize Upstream's platform, allowing global investors to trade using various payment methods, including USDC digital currency. The dual listing aims to enhance liquidity, price discovery, and accessibility for U.S. investors. Nutriband's primary focus is developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing AVERSA™ technology, which is crucial for preventing drug abuse.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has commenced production of its AI Tape brand, with an anticipated launch in Q1 2023. The new product aims to enhance traditional Kinesiology Tape by incorporating therapeutic ingredients in a proprietary adhesive mix. Production is taking place at the company's facility in North Carolina. Nutriband focuses on transdermal pharmaceutical products, developing an abuse deterrent fentanyl patch using its AVERSA™ technology. This aims to prevent drug misuse and accidental exposure.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced its approval for a dual listing on Upstream, with trading set to begin on January 5, 2023. This move aims to enhance liquidity and broaden its investor base by allowing trading in digital currencies like USDC and traditional payment methods. Participants will also receive a commemorative NFT on listing day. CEO Gareth Sheridan highlighted that this listing will facilitate reaching international markets and bolster shareholder value as the company develops its AVERSA™ technology for transdermal products.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) will feature on The RedChip Money Report on Bloomberg TV, airing December 17, 2022, at 7 p.m. ET. The interview will showcase Nutriband's transdermal technology and its applications, led by Chief Scientific Officer Dr. Jeff Patrick. This technology includes the development of an abuse deterrent fentanyl patch utilizing AVERSA™ technology. The segment will be accessible to an estimated 73 million U.S. homes. For full access to the interview, visit here.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) reported a record revenue of $620,000 for Q3 2022, marking a 118% increase from Q3 2021. Year-to-date revenue reached $1,552,074, a 67% year-over-year growth. The company continues to expand its AVERSA™ intellectual property portfolio with patents granted in 44 countries. Net loss decreased to $1.07 million from $1.57 million in the prior year. CEO Gareth Sheridan highlighted potential peak sales for AVERSA Fentanyl could range between $80 million to $200 million.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that CEO Gareth Sheridan will present at the RHK Capital Disruptive Growth Conference on December 5, 2022, at 10:20 AM in New York City. The presentation will focus on the company's AVERSA technology and its market potential. The conference will host executives from up to 30 growth-oriented companies, engaging with institutional investors and financial advisors. Nutriband specializes in transdermal pharmaceutical products, with a lead product under development being an abuse deterrent fentanyl patch utilizing AVERSA technology.
Nutriband Inc. (NTRB, NTRBW) announced the granting of Canadian patent No. 2,937,649 for its AVERSA™ transdermal abuse deterrent technology. The patent issued on November 1, 2022, enhances protection for the AVERSA™ products across North America, following similar patents granted in the U.S. and Mexico. This technology aims to mitigate opioid abuse, particularly in light of Canada's opioid crisis. Nutriband's AVERSA™ Fentanyl system is projected to achieve peak U.S. sales between $80M and $200M, addressing a significant public health issue while ensuring patient access.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) endorses the 2022 CDC guidelines on opioid prescribing, emphasizing the need for abuse deterrent technologies in pain management. The new guidelines allow greater opioid access for those with chronic pain while recognizing the challenges of the prior restrictions. Nutriband's AVERSA™ technology aims to mitigate abuse risks associated with transdermal opioids. The lead product, AVERSA™ Fentanyl, is projected to generate $80M - $200M in potential annual sales post-launch, enhancing safety for vulnerable patient groups.